DVAX – Dynavax Technologies Corporation
Dynavax Technologies CorporatioDVAX
$9.62Name : Dynavax Technologies Corporatio
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $1,155,179,264.00
EPSttm : -0.5
Dynavax Technologies Corporatio
$9.62
2.34%$0.23Float Short %
17.13
Margin Of Safety %
-5
Put/Call OI Ratio
0.72
EPS Next Q Diff
0.3
EPS Last/This Y
-0.42
EPS This/Next Y
0.69
Price
9.62
Target Price
24.52
Analyst Recom
1.8
Performance Q
-24.25
Relative Volume
0.64
Beta
1.09
Ticker: DVAX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | DVAX | 11.44 | 0.28 | 4.50 | 9516 |
| 2025-04-15 | DVAX | 11.4 | 0.28 | 0.02 | 9521 |
| 2025-04-16 | DVAX | 10.65 | 0.28 | 5.55 | 9599 |
| 2025-04-17 | DVAX | 10.31 | 0.28 | 0.15 | 9601 |
| 2025-04-18 | DVAX | 10.31 | 0.28 | 0.09 | 9601 |
| 2025-04-21 | DVAX | 10.44 | 0.20 | 33.57 | 5685 |
| 2025-04-22 | DVAX | 10.73 | 1.28 | 0.03 | 11148 |
| 2025-04-23 | DVAX | 10.76 | 1.24 | 0.04 | 11311 |
| 2025-04-24 | DVAX | 10.9 | 1.22 | 1.39 | 11428 |
| 2025-04-25 | DVAX | 10.82 | 1.2205426356589 | 0.079847908745247 | 11458 |
| 2025-04-28 | DVAX | 11.27 | 1.161534206159 | 1.5384615384615 | 11722 |
| 2025-04-29 | DVAX | 11.55 | 1.16 | 0.53 | 11730 |
| 2025-04-30 | DVAX | 11.76 | 1.16 | 0.00 | 11769 |
| 2025-05-01 | DVAX | 11.48 | 1.16 | 0.00 | 11785 |
| 2025-05-02 | DVAX | 11.33 | 1.14 | 0.50 | 11857 |
| 2025-05-05 | DVAX | 11.26 | 1.14 | 0.02 | 11864 |
| 2025-05-06 | DVAX | 10.9 | 1.12 | 1.26 | 11936 |
| 2025-05-07 | DVAX | 9.7 | 1.13 | 0.05 | 11949 |
| 2025-05-08 | DVAX | 9.69 | 0.99 | 0.18 | 11632 |
| 2025-05-09 | DVAX | 9.45 | 0.99 | 0.01 | 11667 |
| 2025-05-12 | DVAX | 9.85 | 0.73 | 0.12 | 13697 |
| 2025-05-13 | DVAX | 9.6 | 0.72 | 0.49 | 13800 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | DVAX | 11.44 | 164.3 | - | 0.32 |
| 2025-04-15 | DVAX | 11.41 | 164.3 | - | 0.32 |
| 2025-04-16 | DVAX | 10.64 | 164.3 | - | 0.32 |
| 2025-04-17 | DVAX | 10.31 | 138.1 | - | 0.33 |
| 2025-04-18 | DVAX | 10.31 | 138.1 | - | 0.33 |
| 2025-04-21 | DVAX | 10.43 | 138.1 | - | 0.33 |
| 2025-04-22 | DVAX | 10.72 | 138.1 | - | 0.33 |
| 2025-04-23 | DVAX | 10.77 | 138.1 | - | 0.33 |
| 2025-04-24 | DVAX | 10.89 | 138.1 | - | 0.33 |
| 2025-04-25 | DVAX | 10.82 | 138.1 | - | 0.33 |
| 2025-04-28 | DVAX | 11.27 | 138.1 | - | 0.33 |
| 2025-04-29 | DVAX | 11.55 | 138.1 | - | 0.33 |
| 2025-04-30 | DVAX | 11.76 | 138.1 | - | 0.33 |
| 2025-05-01 | DVAX | 11.48 | 138.1 | - | 0.33 |
| 2025-05-02 | DVAX | 11.33 | 138.1 | - | 0.33 |
| 2025-05-05 | DVAX | 11.26 | 138.1 | - | 0.33 |
| 2025-05-06 | DVAX | 10.91 | 138.1 | - | 0.33 |
| 2025-05-07 | DVAX | 9.72 | 138.1 | - | 0.33 |
| 2025-05-08 | DVAX | 9.69 | 8.3 | - | 0.32 |
| 2025-05-09 | DVAX | 9.39 | 75.0 | - | -0.21 |
| 2025-05-12 | DVAX | 9.85 | 75.0 | - | -0.21 |
| 2025-05-13 | DVAX | 9.62 | 75.0 | - | -0.21 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | DVAX | -0.97 | -4.31 | 15.53 |
| 2025-04-15 | DVAX | -0.97 | -4.31 | 15.53 |
| 2025-04-16 | DVAX | -0.97 | -4.31 | 15.53 |
| 2025-04-17 | DVAX | -0.97 | -4.31 | 15.53 |
| 2025-04-18 | DVAX | -0.97 | -4.31 | 15.53 |
| 2025-04-21 | DVAX | -0.97 | -4.51 | 15.53 |
| 2025-04-22 | DVAX | -0.97 | -4.51 | 15.53 |
| 2025-04-23 | DVAX | -0.97 | -4.51 | 15.53 |
| 2025-04-24 | DVAX | -0.99 | -4.51 | 15.76 |
| 2025-04-25 | DVAX | -0.99 | -4.51 | 15.76 |
| 2025-04-28 | DVAX | -0.99 | -4.47 | 15.31 |
| 2025-04-29 | DVAX | -0.99 | -4.47 | 15.31 |
| 2025-04-30 | DVAX | -0.99 | -4.47 | 15.31 |
| 2025-05-01 | DVAX | -0.99 | -4.47 | 15.31 |
| 2025-05-02 | DVAX | -0.99 | -4.47 | 15.31 |
| 2025-05-05 | DVAX | -0.99 | -3.06 | 15.31 |
| 2025-05-06 | DVAX | -0.99 | -3.06 | 15.31 |
| 2025-05-07 | DVAX | -0.99 | -3.06 | 15.31 |
| 2025-05-08 | DVAX | -0.99 | -3.06 | 15.31 |
| 2025-05-09 | DVAX | -1.00 | -3.06 | 15.60 |
| 2025-05-12 | DVAX | -1.00 | -4.60 | 17.13 |
| 2025-05-13 | DVAX | -1.00 | -4.60 | 17.13 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.11
Avg. EPS Est. Current Quarter
0.14
Avg. EPS Est. Next Quarter
0.19
Insider Transactions
-1
Institutional Transactions
-4.6
Beta
1.09
Average Sales Estimate Current Quarter
87
Average Sales Estimate Next Quarter
95
Fair Value
9.15
Quality Score
51
Growth Score
52
Sentiment Score
4
Actual DrawDown %
55
Max Drawdown 5-Year %
-68.1
Target Price
24.52
P/E
Forward P/E
18.01
PEG
P/S
3.92
P/B
2.24
P/Free Cash Flow
21.38
EPS
-0.53
Average EPS Est. Cur. Y
-0.21
EPS Next Y. (Est.)
0.48
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-20.39
Relative Volume
0.64
Return on Equity vs Sector %
-35
Return on Equity vs Industry %
-18.9
EPS 1 7Days Diff
-0.5
EPS 1 30Days Diff
-0.53
EBIT Estimation
Dynavax Technologies CorporatioSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 405
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
stock quote shares DVAX – Dynavax Technologies Corporation Stock Price stock today
news today DVAX – Dynavax Technologies Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch DVAX – Dynavax Technologies Corporation yahoo finance google finance
stock history DVAX – Dynavax Technologies Corporation invest stock market
stock prices DVAX premarket after hours
ticker DVAX fair value insiders trading